Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 11, 2020
PublicationFiclatuzumab

A Multicentre Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile. Click here for link to article.

January 27, 2020
PresentationFiclatuzumab

ASCO GI 2020: Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer

April 1, 2019
PresentationFiclatuzumab

AACR 2019: CyFi: Results from a phase Ib expansion cohort of ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)

October 21, 2018
PresentationFiclatuzumab

ESMO 2018: Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

November 8, 2017
PublicationFiclatuzumab

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Gth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC

Authors: Eng-Huat Tan, Wan-Teck Lim, Myung-Ju Ahn, Quan-Sing Ng, Jin Seok Ahn, Daniel Shao-Weng Tan, Jong-Mu Sun, May Han, Francis C. Payumo, Krista McKee, Wei Yin, Marc Credi, Shefali Agarwal, Jaroslaw Jac, Keunchil Park. Click here for link to article.

June 5, 2017
PresentationFiclatuzumab

ASCO 2017: Phase I study of the anti-HGF monoclonal antibody, ficlatuzumab, and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer

1 2 3 4

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.